Identification
NamePolystyrene sulfonate
Accession NumberDB01344
TypeSmall Molecule
GroupsApproved
DescriptionSodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, HIV. [Wikipedia]
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Calcium polystyrene sulfonateHUI2S00793 37286-92-3IJBYVKWTVVYTPL-UHFFFAOYSA-MDetails
Sodium polystyrene sulfonate1699G8679Z 9080-79-9IJBYVKWTVVYTPL-UHFFFAOYSA-MDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
K-exit PoudrePowder, for solution100 %Oral; RectalOmega Laboratories Ltd1988-12-31Not applicableCanada
KayexalatePowder, for suspension4.1 meq/gOral; RectalCovis Pharmaceuticals, Inc.2013-07-152018-06-30Us
KayexalatePowder100 %Oral; RectalSanofi Aventis1961-12-31Not applicableCanada
PHL-sodium Polystyrene Sulfonate Oral SuspensionSuspension250 mgOralPharmel Inc2004-12-072010-11-25Canada
PHL-sodium Polystyrene Sulfonate PowderPowder94.3 mgOral; RectalPharmel Inc2004-12-072014-02-10Canada
PHL-sodium Polystyrene Sulfonate Retention EnemaSuspension250 mgRectalPharmel Inc2004-12-072010-11-25Canada
Resonium CalciumPowder, for solution999 mgOral; RectalSanofi Aventis1979-12-31Not applicableCanada
SolystatPowder94.3 mgOral; RectalPendopharm Division Of De Pharmascience Inc1988-12-31Not applicableCanada
SolystatSuspension250 mgOralPendopharm Division Of De Pharmascience Inc1989-12-31Not applicableCanada
SolystatSuspension250 mgRectalPendopharm Division Of De Pharmascience Inc1989-12-31Not applicableCanada
Sps Suspension 15gm/60mlSuspension15 gOral; RectalCarolina Medical Products Company1987-12-311999-07-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
KionexSuspension15 g/60mLOral; RectalPaddock Laboratories, Inc.2008-12-30Not applicableUs
KionexPowder, for suspension4.1 meq/gOral; RectalPaddock Laboratories, Inc.1998-02-01Not applicableUs
Sodium Polystyrene SulfonatePowder1 g/gOralMajor2009-11-18Not applicableUs
Sodium Polystyrene SulfonateSuspension15 g/60mLOral; RectalWest Ward Pharmaceutical2013-06-17Not applicableUs
Sodium Polystyrene SulfonatePowder1 g/gOral; RectalAtlantic Biologicals Corps.2012-07-25Not applicableUs
Sodium Polystyrene SulfonatePowder1 g/gOral; RectalKvk Tech,Inc2012-07-25Not applicableUs
Sodium Polystyrene SulfonateSuspension15 g/60mLOral; RectalPaddock Laboratories, Inc.2011-09-21Not applicableUs
Sodium Polystyrene SulfonatePowder1 g/gOral; RectalAtlantic Biologicals Corp.2012-07-25Not applicableUs
Sodium Polystyrene SulfonatePowder, for suspension4.1 meq/gOral; RectalExact Rx, Inc.2012-04-01Not applicableUs
Sodium Polystyrene SulfonatePowder, for suspension4.1 meq/gOralEpic Pharma, LLC2014-04-14Not applicableUs
Sodium Polystyrene SulfonatePowder, for suspension4.1 meq/gOral; RectalSunrise Pharmaceutical, Inc.2017-01-24Not applicableUs
Sodium Polystyrene SulfonatePowder, for suspension4.1 meq/gOral; RectalLeading Pharma, Llc2015-08-12Not applicableUs
Sodium Polystyrene SulfonateSuspension15 g/60mLOral; RectalCmp Pharma, Inc.1982-12-08Not applicableUs
Sodium Polystyrene SulfonatePowder, for suspension4.1 meq/gOralPura Cap Pharmaceutical Llc.2016-12-15Not applicableUs
Sodium Polystyrene SulfonatePowder, for suspension4.1 meq/gOral; RectalBelcher Pharmaceuticals, LLC2016-03-15Not applicableUs
Sodium Polystyrene SulfonatePowder, for suspension1 g/gOral; RectalCmp Pharma, Inc.1989-01-19Not applicableUs
Sodium Polystyrene SulfonatePowder, for suspension4.1 meq/gOral; RectalMarlex Pharmaceuticals Inc2016-03-01Not applicableUs
Sodium Polystyrene SulfonateSuspension15 g/60mLOral; RectalCardinal Health1983-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Resonium ANot Available
SorbisteritNot Available
Brand mixturesNot Available
Categories
UNIIZSL2FB6GXN
CAS number28210-41-5
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationUsed to treat abnormally high potassium levels.
Structured Indications
PharmacodynamicsPolystyrene sulfonate affects the exchange of sodium and potassium in the body. Polystyrene sulfonate is used to treat high levels of potassium in the blood, also called hyperkalemia. It is a potassium-binding ion-exchange resin that can be administered orally (25 grams in 20% sorbitol) or rectally (50 grams in 20% sorbitol).
Mechanism of actionPolystyrene sulfonate, which is not absorbed, binds excess potassium, carrying it out of the body. The indigestible potassium polystryene sulfonate complex is excreted with the faeces, preventing the absorption of potassium into the blood stream. Hence, the serum potassium level decreases.
TargetKindPharmacological actionActionsOrganismUniProt ID
PotassiumSmall moleculeyes
binder
Humannot applicabledetails
Related Articles
AbsorptionNot absorbed following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

none

Route of eliminationFeces.
Half lifenone
ClearanceNot Available
ToxicityOverdose symptoms may include confusion, irritability, trouble thinking or concentrating, muscle weakness, or trouble breathing.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Acetyldigitoxin.Approved
Aluminum hydroxideThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Aluminum hydroxide.Approved
Bismuth SubcitrateThe risk or severity of adverse effects can be increased when Bismuth Subcitrate is combined with Polystyrene sulfonate.Approved
Calcium carbonateThe risk or severity of adverse effects can be increased when Calcium carbonate is combined with Polystyrene sulfonate.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Deslanoside.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Digoxin.Approved
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Polystyrene sulfonate.Approved
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Polystyrene sulfonate.Approved, Vet Approved
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Polystyrene sulfonate.Approved
LithiumThe serum concentration of Lithium can be decreased when it is combined with Polystyrene sulfonate.Approved
MagaldrateThe risk or severity of adverse effects can be increased when Magaldrate is combined with Polystyrene sulfonate.Withdrawn
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Polystyrene sulfonate.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Polystyrene sulfonate.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Magnesium oxide is combined with Polystyrene sulfonate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Polystyrene sulfonate.Approved, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Polystyrene sulfonate.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Polystyrene sulfonate.Approved, Vet Approved
OleandrinThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Anvirzel.Experimental
OuabainThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Ouabain.Approved
Thyroid, porcineThe serum concentration of Thyroid, porcine can be decreased when it is combined with Polystyrene sulfonate.Approved
Food Interactions
  • Avoid calcium, magnesium and potassium.
  • Take on an empty stomach.
References
Synthesis Reference

Chris Ho, Jugminder Chawla, Hitesh R. Bhagat, “Polystyrene sulfonate polymer tablets, their preparation and use.” U.S. Patent US20080299198, issued December 04, 2008.

US20080299198
General ReferencesNot Available
External Links
ATC CodesV03AE01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentPseudohypoaldosteronism1
4CompletedTreatmentChronic Kidney Failure / Hyperkalemia1
4TerminatedSupportive CareHyperkalemia1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionOral; Rectal100 %
PowderOral; Rectal100 %
Powder, for suspensionOral; Rectal4.1 meq/g
SuspensionOral; Rectal15 g/60mL
Powder, for solutionOral; Rectal999 mg
PowderOral1 g/g
PowderOral; Rectal1 g/g
Powder, for suspensionOral4.1 meq/g
Powder, for suspensionOral; Rectal1 g/g
PowderOral; Rectal94.3 mg
SuspensionOral250 mg
SuspensionRectal250 mg
SuspensionOral; Rectal15 g
Prices
Unit descriptionCostUnit
Pms-Sod Polystyr Sulf (120 Ml) 30 g/enm Retention Enema15.36USD enema
Kayexalate Powder0.9USD gm
Kayexalate powder0.86USD g
Sod poly sulfonate powder0.69USD g
Kionex Powder0.46USD gm
Kionex powder0.44USD g
Kalexate powder0.39USD g
Sodium polystyrene sulf powder0.39USD g
Sodium Polystyrene Sulfonate Powder0.31USD gm
Kayexalate Powder0.2USD g
Pms-Sodium Polystyrene Sulf. Powder0.15USD g
Pms-Sodium Polystyrene Sulf. 250 mg/ml Suspension0.13USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
binder
References
  1. Watson M, Abbott KC, Yuan CM: Damned if you do, damned if you don't: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol. 2010 Oct;5(10):1723-6. doi: 10.2215/CJN.03700410. Epub 2010 Aug 26. [PubMed:20798253 ]
  2. Sterns RH, Rojas M, Bernstein P, Chennupati S: Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010 May;21(5):733-5. doi: 10.1681/ASN.2010010079. Epub 2010 Feb 18. [PubMed:20167700 ]
  3. Hoffman RS, Stringer JA, Feinberg RS, Goldfrank LR: Comparative efficacy of thallium adsorption by activated charcoal, prussian blue, and sodium polystyrene sulfonate. J Toxicol Clin Toxicol. 1999;37(7):833-7. [PubMed:10630266 ]
Drug created on June 30, 2007 12:12 / Updated on December 08, 2016 11:11